European Journal of Cancer
Volume 41, Issue 4 , Pages 502-507, March 2005

Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone – finally an effective chemotherapy

Rotterdam Cancer Institute, Erasmus University Medical Center, Department of Medical Oncology, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands

Received 6 December 2004; accepted 7 December 2004.

Abstract 

Until now, the use of systemic chemotherapy for advanced androgen-independent prostate cancer has had very little to offer to patients. However, in 2004, two large randomised trials investigating docetaxel vs. mitoxantrone have both demonstrated survival improvements, and, in one of the trails, improvements in important secondary clinical outcome measures such as pain relief and quality of life measurements. In this current perspective, these two trials are summarised and discussed. It is concluded that, docetaxel every 3 weeks plus low-dose prednisone can be considered standard treatment for patients with androgen-independent disease.

Keywords: Prostate cancer, Androgen-independent, Docetaxel, Prednisone, Chemotherapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(04)00994-3

doi:10.1016/j.ejca.2004.12.007

European Journal of Cancer
Volume 41, Issue 4 , Pages 502-507, March 2005

Article Tools